KKR Stock Plunges 5.02% Amid Share Sale, Rating Downgrade

On April 4, 2025, KKR's stock price dropped by 5.02% in pre-market trading, signaling a significant shift in investor sentiment.

KKR recently announced plans to sell up to $300 million worth of shares in J.B. Chemicals & Pharmaceuticals Limited, which could potentially impact its stock performance. This move represents a 10.2% stake in the company, indicating a strategic decision to divest from a significant holding.

HSBC recently adjusted its rating for KKR, downgrading it from a "buy" to a "hold" while increasing its price target from $153.00 to $173.00. This change in rating reflects a cautious outlook on the stock's near-term prospects, despite the higher price target.

KKR's stock has underperformed compared to its competitors, adding to the overall bearish sentiment. The company's stock has slipped 30.8% from its 52-week high of $170.40, achieved on January 31, and has declined 20.3% over the past three months. This performance indicates a challenging period for the stock, which may continue to influence investor decisions.